Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma

Antonio Facciorusso, Luigi Mariani, Carlo Sposito, Carlo Spreafico, Marco Bongini, Carlo Morosi, Tommaso Cascella, Alfonso Marchianò, Tiziana Camerini, Sherrie Bhoori, Federica Brunero, Michele Barone, Vincenzo Mazzaferro

Research output: Contribution to journalArticlepeer-review


Background and Aim: Solid demonstrations of superior efficacy of drug-eluting beads transarterial chemoembolization with respect to conventional chemoembolization in hepatocellular carcinoma patients are lacking. The aim of the study was to compare these two techniques in two large cohorts of unresectable hepatocellular carcinoma patients. Methods: A single center series of 249 early/intermediate hepatocellular carcinoma patients who underwent "on demand" chemoembolization in the period 2007-2011 was analyzed. Overall survival, time to progression, tumor response rate, and safety were compared between 104 patients who underwent conventional chemoembolization and 145 who underwent drug-eluting beads chemoembolization. Time-to-event data were analyzed using the Cox univariate and multivariate regression. Results: The two cohorts resulted balanced for liver function and tumor stages. Objective response rate was 85.3% after conventional and 74.8% after drug-eluting beads chemoembolization (P=0.039), and median time to progression was 17 (95% confidence interval: 14-21) versus 11months (9-12), respectively (P

Original languageEnglish
Pages (from-to)645-653
Number of pages9
JournalJournal of Gastroenterology and Hepatology
Issue number3
Publication statusPublished - Mar 1 2016


  • HCC
  • Hepatocellular carcinoma
  • Loco-regional treatments
  • TACE

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this